Dec 24, 2025 • MarketBeat
SOMEWHAT-BULLISH
Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Sees Significant Drop in Short Interest
Ascentage Pharma Group International (NASDAQ:AAPG) experienced a significant 84.2% decrease in short interest in December, reducing the total to just 254 shares. Wall Street analysts maintain a "Buy" consensus rating with an average price target of $48.50, and several institutions recently initiated positions in the stock. The company's shares traded up 5.2% to $27.88, demonstrating a quick ratio of 1.53 and a debt-to-equity of 1.31.
Dec 23, 2025 • TipRanks
NEUTRAL
Ascentage Pharma Advances Olverembatinib With New Liver Function Study, Offering Gradual Upside for Investors
Ascentage Pharma Group International (HK:6855) has provided an update on their Phase 1 clinical study for olverembatinib, a cancer drug. The study aims to determine how liver impairment affects the drug's pharmacokinetics to establish safe dosing in patients with varying degrees of liver function. This ongoing trial, while offering incremental news, could lead to broader use and stronger market positioning for olverembatinib, supporting the company's valuation in the long term.
Dec 23, 2025 • Benzinga
NEUTRAL
Novo Nordisk, Sable Offshore, StoneCo And Other Big Stocks Moving Higher On Tuesday
Several stocks, including Novo Nordisk, Sable Offshore, and StoneCo, are seeing significant gains on Tuesday. Novo Nordisk surged after FDA approval for its Wegovy pill, while Sable Offshore benefited from the approval of restart plans for its Las Flores Pipeline system. StoneCo saw a rise following authorization for a new share repurchase program.
Dec 21, 2025 • Simply Wall Street
NEUTRAL
Assessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax
Ascentage Pharma (SEHK:6855) revealed new long-term data for Olverembatinib and Lisaftoclax at the ASH 2025 Annual Meeting, impacting its valuation. While analyst narratives suggest the stock is significantly undervalued, a Discounted Cash Flow (DCF) model indicates it may be trading above its intrinsic value. The article highlights the discrepancy between these valuation methods and the market's current assessment of Ascentage's growth prospects, especially given its R&D spending and reliance on China-focused revenues.
Dec 21, 2025 • Simply Wall Street
NEUTRAL
Assessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax
Ascentage Pharma Group International (SEHK:6855) showcased new long-term data on Olverembatinib and Lisaftoclax at the ASH 2025 Annual Meeting. Despite recent share price declines, the company shows stronger long-term momentum, trading at a discount to analyst estimates despite double-digit revenue growth. While a narrative valuation suggests the stock is undervalued, Simply Wall St's DCF model implies it might be trading above its intrinsic value, prompting investors to consider whether the market is overly optimistic about future cash flow.
Dec 20, 2025 • MarketBeat
BULLISH
Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of "Buy" by Brokerages
Six brokerages have issued a consensus "Buy" rating for Ascentage Pharma Group International (NASDAQ:AAPG), with an average 1-year price target of $48.50, significantly higher than its current ~$29 share price. Analyst coverage has increased with targets ranging from $45-$51, and institutional investors like UBS and XY Capital have substantially increased their holdings, while Tema ETFs, HSBC, and Citadel have established new stakes. Ascentage Pharma is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for various cancers.